We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Supreme Court Won’t Hear Sandoz’s Appeal on Enbrel Patent Ruling
Supreme Court Won’t Hear Sandoz’s Appeal on Enbrel Patent Ruling
Novartis subsidiary Sandoz failed to persuade the U.S. Supreme Court to review a federal circuit ruling that blocked the drugmaker from launching a copycat drug of Amgen’s autoimmune blockbuster Enbrel (etanercept).